A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease
This study aims to investigate whether orforglipron can reduce the risk of serious health problems related to the heart and blood vessels. The research focuses on individuals living with Atherosclerotic Cardiovascular Disease, a condition where plaque builds up in the arteries, and or Chronic Kidney Disease, which is a long-term condition where the kidneys do not work as well as they should. Participants will be given either orforglipron, which is an oral tablet, or a placebo.
During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.
Who Can Join the Study?
You must have heart disease, which means a problem with the heart or blood vessels.
You must have kidney disease, which means your kidneys are not working as well as they should.
You may have both heart disease and kidney disease.
You must have atherosclerosis cardiovascular disease, which is a condition where the arteries (the tubes that carry blood through your body) become hardened and narrow due to a buildup of fats and cholesterol.
You must be part of the patient group.
You must be within the specified age range, which corresponds to being between 3 and 17 years old based on the provided codes.
The study includes both females and males.
Who Cannot Join the Study?
You cannot participate if you have type 1 diabetes, which is a condition where the body does not produce the insulin needed to manage blood sugar levels.
You cannot participate if you have experienced a serious heart condition within 60 days before the study starts.
You cannot participate if you have NYHA Class IV heart failure, which is the most severe stage of heart failure where symptoms of heart failure occur even while at rest.
Hznhpulk Ueixqodikoaunu Stkesstruj &udwqdi Hbipkfj db Hjghiyvvucm
STRASBOURG, Alsace
France
Want to learn more about this study or check if you can participate? Contact us.
Trial status
Country
Status
Recruitment Start
Austria
Recruiting
01.02.2026
Belgium
Recruiting
01.02.2026
Bulgaria
Recruiting
01.02.2026
Czechia
Recruiting
01.02.2026
Estonia
Recruiting
01.02.2026
France
Recruiting
01.02.2026
Germany
Recruiting
01.02.2026
Greece
Recruiting
01.02.2026
Hungary
Recruiting
01.02.2026
Italy
Recruiting
01.02.2026
Lithuania
Recruiting
01.02.2026
Poland
Recruiting
01.02.2026
Romania
Recruiting
01.02.2026
Slovakia
Recruiting
01.02.2026
Spain
Recruiting
01.02.2026
The Netherlands
Recruiting
01.02.2026
Trial locations
Orforglipron is an oral medication being studied to see if it can help reduce the risk of major heart-related problems in people who already have heart disease or kidney disease.
Chronic Kidney Disease – This condition occurs when the kidneys gradually lose their ability to filter waste products from the blood. As the disease progresses, the kidneys become less efficient at maintaining the body’s fluid and chemical balance. This decline can lead to an accumulation of harmful substances in the body. The damage often develops slowly over many years.
Atherosclerosis Cardiovascular Disease – This condition involves the buildup of fats, cholesterol, and other substances in and on the artery walls. These deposits, known as plaques, cause the arteries to narrow and harden over time. As the arteries become more restricted, blood flow to vital organs and tissues is reduced. This process can eventually lead to serious complications involving the heart or brain.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.